<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365624</url>
  </required_header>
  <id_info>
    <org_study_id>ROX 2007-02</org_study_id>
    <nct_id>NCT01365624</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects</brief_title>
  <official_title>A Phase 1 Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luitpold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luitpold Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study had an open-label, single-dose design. All subjects received a single dose of 30
      mg of intranasal ketorolac. Blood samples for determination of ketorolac plasma levels were
      obtained pre-dose and at specified time points over 24 hours post-dose.

      The primary objective of this trial was to compare the pharmacokinetics of intranasal
      ketorolac between elderly and nonelderly adult subjects. The secondary objective was to
      evaluate the safety profile of intranasal ketorolac in elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Plasma Concentration)</measure>
    <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time to Reach Maximum Plasma Concentration)</measure>
    <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast (Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Time Point Post-dose</measure>
    <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (Area Under the Plasma Concentration-time Profile From Time 0 to Infinity</measure>
    <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2z (Terminal Half-life)</measure>
    <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT (Mean Residence Time)</measure>
    <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac tromethamine</intervention_name>
    <description>Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
    <arm_group_label>Ketorolac tromethamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The elderly population consisted of male or female volunteers aged &gt; of = 65 years

          -  The nonelderly adult population consisted of male or female volunteers aged &lt; 65 years

          -  Generally good health in the opinion of the Investigator, as determined by a prestudy
             physical examination with no clinically significant abnormalities for age, vital signs
             within normal ranges or outside normal range but not deemed clinically significant for
             age in the opinion of the Investigator, and no clinically significant
             electrocardiogram (ECG) abnormalities for age

          -  Bilaterally patent nasal airways at screening as assessed by the Investigator

          -  Body mass index (BMI) 15-30 kg/m2

          -  Female subjects of childbearing potential must consent to use a medically acceptable
             method of contraception (oral or implanted contraceptive hormones, condom or diaphragm
             with spermicidal agent, intrauterine device, or surgical sterilization) throughout the
             study period

          -  Ability to provide written informed consent

          -  Prestudy clinical laboratory findings within normal ranges or if outside normal range
             not deemed clinically significant for age in the opinion of the Investigator

        Exclusion Criteria:

          -  Allergy or sensitivity to ketorolac or formulation ingredients

          -  History of co-existing nasal polyps, NSAID sensitivity, and asthma

          -  Allergic reaction to aspirin or other NSAIDs

          -  Current upper respiratory tract infection or other respiratory tract condition that
             could interfere with the absorption of the nasal spray or with the assessment of AEs

          -  Use of any prescribed or over-the-counter (OTC) drug in the 72 h prior to entry into
             the study with the exception of occasional acetaminophen up to 24 h prior to entry

          -  Suspicion of rhinitis medicamentosa (chronic daily use of topical decongestants)

          -  Use of a monoamine oxidase (MAO) inhibitor in the 14 days prior to study entry

          -  Positive serum test for human immunodeficiency virus (HIV) or hepatitis B or C

          -  Positive alcohol breath test at screening or on entry into the study

          -  Positive urine screen for any nonprescribed drug of abuse at screening or on entry
             into the study

          -  History of cocaine use

          -  Blood donation within 30 days of beginning study participation

          -  Active peptic ulcer disease or a history of peptic ulcer disease or gastrointestinal
             bleeding

          -  Serum creatinine &gt; 2.0 mg/dL

          -  Current tobacco use or a past history of smoking within 5 years of study entry

          -  Any other clinically significant medical problem, which in the opinion of the
             Investigator would interfere with study participation

          -  Participation within 30 days of study entry or within 5 times the half-life, whichever
             is longer, in another investigational drug study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lincoln Bynum, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ICON Developmental Solutions</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seaview Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <results_first_submitted>August 2, 2012</results_first_submitted>
  <results_first_submitted_qc>January 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2013</results_first_posted>
  <last_update_submitted>January 3, 2013</last_update_submitted>
  <last_update_submitted_qc>January 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>February 2008 through April 2008; Clinical Unit</recruitment_details>
      <pre_assignment_details>After subjects had given their informed consent, subjects were required to pass a screening visit within 3 weeks prior to study drug administration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
          <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
        </group>
        <group group_id="P2">
          <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
          <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
          <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
          <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.9" spread="5.9"/>
                    <measurement group_id="B2" value="44.2" spread="10.3"/>
                    <measurement group_id="B3" value="58.1" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Plasma Concentration)</title>
        <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Plasma Concentration)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1782.286" spread="1184.843"/>
                    <measurement group_id="O2" value="1840.111" spread="995.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax (Time to Reach Maximum Plasma Concentration)</title>
        <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax (Time to Reach Maximum Plasma Concentration)</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.750" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.750" lower_limit="0.25" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUClast (Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Time Point Post-dose</title>
        <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast (Area Under the Plasma Concentration-time Profile From Time Zero to the Last Quantifiable Time Point Post-dose</title>
          <units>ng*hours/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7323.5" spread="4633.1"/>
                    <measurement group_id="O2" value="6536.5" spread="3361.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (Area Under the Plasma Concentration-time Profile From Time 0 to Infinity</title>
        <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
        <population>Two subjects had abnormally low plasma ketorolac concentration-time profiles that were inconsistent with the rest of the elderly population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (Area Under the Plasma Concentration-time Profile From Time 0 to Infinity</title>
          <population>Two subjects had abnormally low plasma ketorolac concentration-time profiles that were inconsistent with the rest of the elderly population.</population>
          <units>ng*hours/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8794.8" spread="4129.4"/>
                    <measurement group_id="O2" value="6890.8" spread="3448.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>t1/2z (Terminal Half-life)</title>
        <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
        <population>Two subjects had abnormally low plasma ketorolac concentration-time profiles that were inconsistent with the rest of the elderly population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2z (Terminal Half-life)</title>
          <population>Two subjects had abnormally low plasma ketorolac concentration-time profiles that were inconsistent with the rest of the elderly population.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.521" spread="1.142"/>
                    <measurement group_id="O2" value="3.313" spread="0.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MRT (Mean Residence Time)</title>
        <time_frame>Blood samples for PK analyses were obtained at pre-dose (15 minutes prior to ketorolac administration), 15 minutes, 30 minutes, 45 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 15 hours and 24 hours post-dose</time_frame>
        <population>Two subjects had abnormally low plasma ketorolac concentration-time profiles that were inconsistent with the rest of the elderly population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
            <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
          </group>
        </group_list>
        <measure>
          <title>MRT (Mean Residence Time)</title>
          <population>Two subjects had abnormally low plasma ketorolac concentration-time profiles that were inconsistent with the rest of the elderly population.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.024" spread="1.496"/>
                    <measurement group_id="O2" value="4.441" spread="1.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month and 1 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketorolac Tromethamine (Elderly Adults ≥ 65)</title>
          <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
        </group>
        <group group_id="E2">
          <title>Ketorolac Tromethamine (Nonelderly Adults &lt; 65)</title>
          <description>Ketorolac tromethamine : Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Bregman, M.D., Ph.D</name_or_title>
      <organization>Luitpold Pharmaceuticals, Inc.</organization>
      <phone>610-650-4200 ext 828</phone>
      <email>dbregman@lpicrd.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

